Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.

MLA

Krueger, Janna, et al. “Hydroxychloroquine (HCQ) Decreases the Benefit of Anti-PD-1 Immune Checkpoint Blockade in Tumor Immunotherapy.” PLoS ONE, vol. 16, no. 6, June 2021, pp. 1–20. EBSCOhost, https://doi.org/10.1371/journal.pone.0251731.

APA

Krueger, J., Santinon, F., Kazanova, A., Issa, M. E., Larrivee, B., Kremer, R., Milhalcioiu, C., & Rudd, C. E. (2021). Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. PLoS ONE, 16(6), 1–20. https://doi.org/10.1371/journal.pone.0251731

Chicago

Krueger, Janna, Francois Santinon, Alexandra Kazanova, Mark E. Issa, Bruno Larrivee, Richard Kremer, Catalin Milhalcioiu, and Christopher E. Rudd. 2021. “Hydroxychloroquine (HCQ) Decreases the Benefit of Anti-PD-1 Immune Checkpoint Blockade in Tumor Immunotherapy.” PLoS ONE 16 (6): 1–20. doi:10.1371/journal.pone.0251731.